Working with the body to fight cancer, not against it
Allowing lower, better-tolerated doses of chemotherapy and radiotherapy
A disruptive technology to transform the management of cancer
Aiming to move cancer treatments from extending lives to saving lives

Our Science

Veyonda is a first-in-class activator of the innate immune system. This is the system that scientists increasingly are beginning to see must be activated if a cancer is to have any chance of being permanently eradicated.

Pipeline and Clinical Trials

Establishing Veyonda as an essential adjunct to radiotherapy in the treatment of prostate cancer and discharging portfolio risk by studying Veyonda in combination with radiotherapy and non-radio therapy treatments.


February 13-15, 2020
ASCO GU Conference - LuPIN Trial interim data to be presented by A/Prof L Emmett - Director of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney
San Francisco, California, USA
February 27, 2020
Kalkine Invest-Nest 2020
Karstens Sydney, 111 Harrington Street ,The Rocks, NSW 2000
November 12-14, 2019
COSA Annual Meeting - Adelaide, SA
November 20, 2019
Noxopharm 2019 AGM - Sydney, NSW